Company Of The Day: Roche
What?
Healthcare major Roche (OTCMKTS:RHHBY) reported that its Q1 2022 group sales rose 11% year-over-year on a constant currency basis to CHF 16.45 billion (about $17.7 billion).
Why?
Growth was driven by the diagnostics division, which saw robust demand for Covid-19 tests and a recovery in the base business. The pharma division grew by about 6%.
So What?
However, the company sees a slowdown in Covid-19 driven sales growth. For the full year, it expects that total sales could grow in the low-single digits in constant currency terms while guiding for adjusted earnings growth in the low to mid-single-digit range.
See Our Complete Analysis For Roche
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
| Returns | Apr 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| RHHBY Return | -3% | -7% | 68% |
| S&P 500 Return | -6% | -10% | 91% |
| Trefis Multi-Strategy Portfolio | -6% | -13% | 243% |
[1] Month-to-date and year-to-date as of 4/26/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates